A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.
about
Efficacy and safety of different molecular targeted agents based on chemotherapy for gastric cancer patients treatment: a network meta-analysisA unified model of the hierarchical and stochastic theories of gastric cancer.Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.In situ analysis of FGFR2 mRNA and comparison with FGFR2 gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients.Update on Gastroesophageal Adenocarcinoma Targeted Therapies.Immunotherapy for gastric cancers: emerging role and future perspectives.Challenges in molecular targeted therapy for gastric cancer: considerations for efficacy and safety.Novel Targeted Therapies for Esophagogastric Cancer.Underlying Mechanisms for Distant Metastasis - Molecular Biology.The relative efficacy and safety of targeted agents used in combination with chemotherapy in treating patients with untreated advanced gastric cancer: a network meta-analysis.Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer.Targeting MET in cancer therapy.New therapeutic options opened by the molecular classification of gastric cancer.Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in epidermal growth factor receptor-2-negative, mesenchymal-epithelial transition-positive gastroesophageal adenocarcinoma: is it a real failure?
P2860
Q33441654-2D439835-E4D4-4E98-A8D2-E9D037A93D6DQ33577624-8D7B61CE-80D3-48EC-9EDC-A801B8DB82ECQ36307708-B69347C9-9F6F-4638-8C0F-37D00EBA2B20Q38602669-517C1B17-8C84-44E6-9522-D3DF81D552B3Q38684349-EE1395D6-C197-4F8B-880D-00644BEA1B34Q38738652-35312C3E-C581-4D8D-8554-CDACF26B33B3Q39038994-E2C09B1E-8DFF-4D46-8B67-D6766DE306A1Q39171565-13C0F77C-1616-4B54-A068-257AF31BCA4FQ40102636-FB1358A1-CDCA-4915-AED9-C29D0095EEECQ42265610-2CE230A0-1358-46D9-A376-31811852BC78Q42693879-83A39D35-0A26-4D7B-9B92-D87D26E185A5Q47402625-E7EA8C08-22ED-427C-85BC-A6BBAAFD4568Q54987450-AF923402-9DC6-4A2A-870E-7C53D89336EFQ55527185-2AAD820C-05AA-46E7-8D2C-25DA3FF17D1CQ58555802-56081CC8-8D37-4153-9528-342E645D9292
P2860
A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
A Randomized Phase II Study of ...... and Gastroesophageal Junction.
@en
type
label
A Randomized Phase II Study of ...... and Gastroesophageal Junction.
@en
prefLabel
A Randomized Phase II Study of ...... and Gastroesophageal Junction.
@en
P2093
P2860
P1433
P1476
A Randomized Phase II Study of ...... and Gastroesophageal Junction
@en
P2093
Alice Kang
Chia-Jui Yen
David S Shames
Iain B Tan
Manish A Shah
Niall C Tebbutt
Yoon-Koo Kang
P2860
P304
P356
10.1634/THEONCOLOGIST.2016-0038
P50
P577
2016-07-08T00:00:00Z